Interested in sharing the research? You can order print copies of many research publications.

Order Reprints

Newsletter Sign-Up

Keep up to date with NPC news and events by signing up for our e-newsletter E.V.I.dently, and our CER Daily Newsfeed.

Subscribe POLICY

The Productivity Crisis in Pharmaceutical R&D

Advances in the understanding of the molecular basis of diseases have expanded the number of plausible therapeutic targets for the development of innovative agents in recent decades. However, although investment in pharmaceutical research and development (R&D) has increased substantially in this time, the lack of a corresponding increase in the output in terms of new drugs being approved indicates that therapeutic innovation has become more challenging. What is driving firm efforts in R&D and what has contributed to the R&D productivity slowdown in recent years?

To answer those questions, researchers used a large database that contains information on R&D projects for more than 28,000 compounds investigated since 1990, and examined the decline of R&D productivity in pharmaceuticals in the past two decades and its determining factors. They found that this decline is associated with an increasing concentration of R&D investments in areas in which the risk of failure is high, which correspond to unmet therapeutic needs and unexploited biological mechanisms. They also investigated the potential variations in productivity with regard to the regional location of companies and found that although companies based in the United States and Europe differ in the composition of their R&D portfolios, there is no evidence of any productivity gap.

Key Points:

  • The decline in pharmaceutical R&D productivity is accompanied by a greater focus on unmet therapeutic needs and biological mechanisms that have not been explored as therapeutic targets.
  • Through their payment policies, public and private payers have discouraged development of “me too” drugs, and the response is research to develop new products in therapeutic areas where finding a cure may be more difficult and take longer.
  • Although at first glance the European R&D effort appears to be more productive than the U.S., the greater and more successful biotechnology effort in the U.S. illustrates the higher risk profile of U.S. R&D. The difference in productivity between the U.S. and Europe disappears with appropriate adjustment to reflect the higher risk nature of research in the U.S.

This research was funded, in part, by grants from the National Pharmaceutical Council, AstraZeneca Pharmaceuticals, Novartis Pharmaceuticals, and Pfizer.

Due to copyright issues, the article must be downloaded from the Nature Reviews website.

Commentary and Testimony Page

The Importance of Evidence, Value, Access and Innovation in 2016

Last year, in our 2015 Health Care Outlook published in Chain Drug Review, I highlighted the recent announcement by the U.S. Department of Health and...
Newsletter Volume

E.V.I.dently November 2015

MessageCan We Work Together to Ensure Patient Access to Treatments and Encourage Innovation?Has biopharmaceutical innovation brought value and made a...
Blog Post

Can We Work Together to Ensure Patient Access to Treatments and Encourage Innovation?

Is it possible for all health care stakeholders to work together to develop solutions for containing costs that ensure patient access to care and...
Blog Post

Pharmaceutical Innovation’s Role in the Panorama of Health System Improvement and Population Health

When he announced the launch of the White House Precision Medicine Initiative, President Obama said, “If we have the opportunity to prevent hurt and...
Press Release

Specialty Medications: Shifting the Focus From “How Much” We Spend to “How Well” We Spend

Washington, DC, June 9, 2014—As health care decision-makers grapple with how to ensure access to specialty medications, the University of Michigan...
Press Release

National Pharmaceutical Council Welcomes Amgen as Its Newest Member

Washington, D.C. (January 16, 2013)—The National Pharmaceutical Council (NPC) today welcomed biotechnology pioneer Amgen as its newest member. Joshua...
Press Release

National Pharmaceutical Council Expands Policy and Research Staff

WASHINGTON, DC (January 4, 2012) -- The National Pharmaceutical Council (NPC) announced the hiring of Daryl Pritchard, PhD, as the Director of...
Press Release

National Pharmaceutical Council Welcomes New Member, Otsuka America Pharmaceutical, Inc.

Washington, DC (December 21, 2009) –The National Pharmaceutical Council (NPC) today announced that Otsuka America Pharmaceutical, Inc. has joined the...
Commentary and Testimony Page

The Importance of Evidence, Value, Access and Innovation in 2016

Last year, in our 2015 Health Care Outlook published in Chain Drug Review, I highlighted the recent announcement by the U.S. Department of Health and...
Commentary and Testimony Page

Medicare Part D, Adherence, and the Value of Pharmaceuticals

Before enactment of the health care reform legislation two years ago, the most significant change in the health care landscape over the past decade...
Commentary and Testimony Page

Health Care Reform and Pharmaceutical Innovation

Although the Patient Protection and Affordable Care Act of 2010 (PPACA) is expected to have broad societal benefits, moving forward, it will be...
Commentary and Testimony Page

Comments on “The NCCN Comparative Therapeutic Index TM as a Paradigm

The National Pharmaceutical Council (NPC) appreciates this opportunity to comment on the proposed “The NCCN Comparative Therapeutic Index ™ as a...
YouTube Videos

CER and Its Impact on Pharma Innovation

Dr. Darius Lakdawalla, director of research at the Schaeffer Center for Health Policy and Economics at the University of Southern California,...
YouTube Videos

Data Mining and Individual Treatment Effects

Dr. Robert Epstein, former chief medical officer and senior vice president of medical affairs at Medco Health, explains how the growth in the use of...
YouTube Videos

CER and HTA: A View From the UK

Dr. Michael Drummond, professor of Health Economics at the University of York, UK, explains the differences between health technology assessments (...
YouTube Videos

CER & Pharmaceutical Industry Free Speech Issues

Covington and Burling Partner Jerry Masoudi outlines pending court cases and how those could affect the way in which the pharmaceutical industry is...
Blog Post

Can We Work Together to Ensure Patient Access to Treatments and Encourage Innovation?

Is it possible for all health care stakeholders to work together to develop solutions for containing costs that ensure patient access to care and...
Blog Post

Pharmaceutical Innovation’s Role in the Panorama of Health System Improvement and Population Health

When he announced the launch of the White House Precision Medicine Initiative, President Obama said, “If we have the opportunity to prevent hurt and...
Blog Post

At the HHS Pharmaceutical Forum, We Need to Consider All Health Care Costs

On November 20, stakeholders will come together for a day-long event—“HHS Pharmaceutical Forum: Innovation, Access, Affordability and Better Health”—...
Blog Post

Value Is in the Eye of the Beholder? NPC Takes Closer Look at ICER Framework

In recent months, a number of health organizations have developed “value assessment frameworks,” which are designed to inform coverage and treatment...

Pharmaceutical Technology Assessment: Perspectives From Payers

The processes and evidence used in making pharmaceutical coverage decisions vary substantially...

Framing the Debate- Untangling the Potential Impact of Comparative Effectiveness Research on Innovation

Researchers integrated expert insight from a roundtable discussion into their own market research...
  •  
  • 1 of 3
  • >